466,663 research outputs found
How to get all trials reported: audit, better data, and individual accountability.
Reflecting on the new WHO statement on clinical trial registration and reporting, Ben Goldacre proposes simple solutions for ensuring clinical trial results are made publicly available
Prototype of running clinical trials in an untrustworthy environment using blockchain.
Monitoring and ensuring the integrity of data within the clinical trial process is currently not always feasible with the current research system. We propose a blockchain-based system to make data collected in the clinical trial process immutable, traceable, and potentially more trustworthy. We use raw data from a real completed clinical trial, simulate the trial onto a proof of concept web portal service, and test its resilience to data tampering. We also assess its prospects to provide a traceable and useful audit trail of trial data for regulators, and a flexible service for all members within the clinical trials network. We also improve the way adverse events are currently reported. In conclusion, we advocate that this service could offer an improvement in clinical trial data management, and could bolster trust in the clinical research process and the ease at which regulators can oversee trials
Parents' perceived obstacles to pediatric clinical trial participation: Findings from the clinical trials transformation initiative.
Enrollment of children into pediatric clinical trials remains challenging. More effective strategies to improve recruitment of children into trials are needed. This study used in-depth qualitative interviews with parents who were approached to enroll their children in a clinical trial in order to gain an understanding of the barriers to pediatric clinical trial participation. Twenty-four parents whose children had been offered the opportunity to participate in a clinical trial were interviewed: 19 whose children had participated in at least 1 clinical trial and 5 who had declined participation in any trial. Each study aspect, from the initial explanation of the study to the end of the study, can affect the willingness of parents to consent to the proposed study and future studies. Establishing trust, appropriate timing, a transparent discussion of risks and benefits oriented to the layperson, and providing motivation for children to participate were key factors that impacted parents' decisions. In order for clinical trial accrual to be successful, parents' priorities and considerations must be a central focus, beginning with initial trial design. The recommendations from the parents who participated in this study can be used to support budget allocations that ensure adequate training of study staff and improved staffing on nights and weekends. Studies of parent responses in outpatient settings and additional inpatient settings will provide valuable information on the consent process from the child's and parent's perspectives. Further studies are needed to explore whether implementation of such strategies will result in improved recruitment for pediatric clinical trials
Recommended from our members
Comparison of Bayesian and frequentist group-sequential clinical trial designs
Background: There is a growing interest in the use of Bayesian adaptive designs in late-phase clinical trials. This
includes the use of stopping rules based on Bayesian analyses in which the frequentist type I error rate is controlled as
in frequentist group-sequential designs.
Methods: This paper presents a practical comparison of Bayesian and frequentist group-sequential tests. Focussing
on the setting in which data can be summarised by normally distributed test statistics, we evaluate and compare
boundary values and operating characteristics.
Results: Although Bayesian and frequentist group-sequential approaches are based on fundamentally different
paradigms, in a single arm trial or two-arm comparative trial with a prior distribution specified for the treatment
difference, Bayesian and frequentist group-sequential tests can have identical stopping rules if particular critical values
with which the posterior probability is compared or particular spending function values are chosen. If the Bayesian
critical values at different looks are restricted to be equal, O’Brien and Fleming’s design corresponds to a Bayesian
design with an exceptionally informative negative prior, Pocock’s design to a Bayesian design with a non-informative
prior and frequentist designs with a linear alpha spending function are very similar to Bayesian designs with slightly
informative priors.
This contrasts with the setting of a comparative trial with independent prior distributions specified for treatment
effects in different groups. In this case Bayesian and frequentist group-sequential tests cannot have the same
stopping rule as the Bayesian stopping rule depends on the observed means in the two groups and not just on their
difference. In this setting the Bayesian test can only be guaranteed to control the type I error for a specified range of
values of the control group treatment effect.
Conclusions: Comparison of frequentist and Bayesian designs can encourage careful thought about design
parameters and help to ensure appropriate design choices are made
Trials, Tricks and Transparency: How Disclosure Rules Affect Clinical Knowledge
Scandals of selective reporting of clinical trial results by pharmaceutical firms have underlined the need for more transparency in clinical trials. We provide a theoretical framework which reproduces incentives for selective reporting and yields three key implications concerning regulation. First, a compulsory clinical trial registry complemented through a voluntary clinical trial results database can implement full transparency (the existence of all trials as well as their results is known). Second, full transparency comes at a price. It has a deterrence effect on the incentives to conduct clinical trials, as it reduces the firms' gains from trials. Third, in principle, a voluntary clinical trial results database without a compulsory registry is a superior regulatory tool; but we provide some qualified support for additional compulsory registries when medical decision-makers cannot anticipate correctly the drug companies' decisions whether to conduct trials.pharmaceutical firms, strategic information transmission, clinical trials, registries, results databases, scientific knowledge.
The Role of Functional, Social, and Mobility Dynamics in Facilitating Older African Americans Participation in Clinical Research
Purpose: Older African Americans experience disproportionately higher incidence of morbidity and mortality related to chronic and infectious diseases, yet are significantly underrepresented in clinical research compared to other racial and ethnic groups. This study aimed to understand the extent to which social support, transportation access, and physical impediments function as barriers or facilitators to clinical trial recruitment of older African Americans. Methods: Participants (N=221) were recruited from six African American churches in Atlanta and surveyed on various influences on clinical trial participation
Designing antifilarial drug trials using clinical trial simulators
Lymphatic filariasis and onchocerciasis are neglected tropical diseases (NTDs) targeted for elimination by mass (antifilarial) drug administration. These drugs are predominantly active against the microfilarial progeny of adult worms. New drugs or combinations are needed to improve patient therapy and to enhance the effectiveness of interventions in persistent hotspots of transmission. Several therapies and regimens are currently in (pre-)clinical testing. Clinical trial simulators (CTSs) project patient outcomes to inform the design of clinical trials but have not been widely applied to NTDs, where their resource-saving payoffs could be highly beneficial. We demonstrate the utility of CTSs using our individual-based onchocerciasis transmission model (EPIONCHO-IBM) that projects trial outcomes of a hypothetical macrofilaricidal drug. We identify key design decisions that influence the power of clinical trials, including participant eligibility criteria and post-treatment follow-up times for measuring infection indicators. We discuss how CTSs help to inform target product profiles
Extraction socket preservation using porcine-derived collagen membrane alone or associated with porcine-derived bone. Clinical results of randomized controlled study
The aim of present randomized controlled clinical trial was to clinically evaluate hard tissue changes after extraction socket preservation procedures compared to natural spontaneous healing
- …